Huasun Technology: Net loss of 42.9413 million yuan in the third quarter

Huasun announced that its revenue for the third quarter was 166 million yuan, a decrease of 19.26%; the net profit loss was 42.9413 million yuan. Revenue for the first three quarters was 457 million yuan, a decrease of 31.02%; the net profit loss was 97.7853 million yuan

Huasun Technology: The listing transfer of 51% equity in Tibet Kangyu has its reserve price adjusted to 52 million yuan

Huasun announced that the company is publicly listing for transfer 51% equity of its controlling subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd. The initial listing price is set at RMB 63.7806 million, but due to the lack of qualified interested buyers, the price will be adjusted to RMB 52 million and will be relisted at the Southwest United Property Rights Exchange. This transaction is a public listing transfer, and the transaction counterpart and price are yet to be determined, presenting significant uncertainty and investment risk. If the transaction is successfully implemented, the company will fulfill its information disclosure obligations in a timely manner based on the progress

Huasun plans to publicly list and transfer 51% equity of Tibet Kangyu

According to the Zhitong Finance APP, Huasun announced that the company plans to publicly transfer 51% of the equity of its controlling subsidiary Tibet Kangyu Pharmaceutical Co., Ltd. (referred to as "Tibet Kangyu") at a listing price of 63.7806 million yuan. The equity transfer will be conducted through public listing at the Southwest United Property Rights Exchange, and the buyer has not yet been determined

Huasun shareholders Yuanhong Biotechnology have cumulatively reduced their holdings in the company by 1.47%

Huasun's shareholder, Yuanhong Biotechnology Co., Ltd., reduced its holdings by 9.14 million shares through the Shenzhen Stock Exchange from May 14, 2025, to July 16, 2025, totaling a reduction of 1.47% of its shares

CHENGDU HUASUN TECHNOLOGY GROUP <> SAYS ITS UNIT TO SELL 5.4% STAKE IN LINKCHEM TECHNOLOGY FOR 200 MLN YUAN